What is Nektar Therapeutics's stock-based comp?

Nektar Therapeutics (NKTR) reported stock-based comp of $3.36M in Q1 2026.

How has Nektar Therapeutics's stock-based comp changed year-over-year?

Nektar Therapeutics's stock-based comp decreased by 13.9% year-over-year, from $3.9M to $3.36M.

What is the long-term trend for Nektar Therapeutics's stock-based comp?

Over 4 years (2021 to 2025), Nektar Therapeutics's stock-based comp has grown at a -39.5% compound annual growth rate (CAGR), from $94.67M to $12.65M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Nektar Therapeutics NKTR Stock-Based Comp

Stock-Based Comp at other companies

AmgenAMGN

$75M-11.8%

Regeneron PharmaceuticalsREGN

$257.4M+0.7%

ImmunityBio, Inc.IBRX

$8.17M-14.3%

Apogee Therapeutics, Inc.APGE

$17.16M+54.2%

ImmunomeIMNM

$7.95M+39.5%

Vera TherapeuticsVERA

$13.21M+70.6%

Segments

By segment

See full

All Other Segments$3.36M-13.9%

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.25B+1,531%

Enterprise value$2.33B+874%

P/S40.5×+38.9×

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's stock-based comp?: Nektar Therapeutics (NKTR) reported stock-based comp of $3.36M in Q1 2026.
How has Nektar Therapeutics's stock-based comp changed year-over-year?: Nektar Therapeutics's stock-based comp decreased by 13.9% year-over-year, from $3.9M to $3.36M.
What is the long-term trend for Nektar Therapeutics's stock-based comp?: Over 4 years (2021 to 2025), Nektar Therapeutics's stock-based comp has grown at a -39.5% compound annual growth rate (CAGR), from $94.67M to $12.65M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.